ALK and non-small cell lung carcinoma: This open-labeled, randomized study in untreated patients with stage IIIB/IV ALK-positive non-squamous NSCLC showed that ceritinib displayed superiority, over platinum-based chemotherapy, as the first-line treatment in these patients [137].